Trial Profile
A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and as Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-412)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 29 Feb 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Cisplatin
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-412
- Sponsors Merck Sharp & Dohme
- 21 Feb 2024 Planned End Date changed from 29 Jun 2024 to 16 Aug 2024.
- 07 Dec 2022 Planned End Date changed from 29 Jun 2023 to 29 Jun 2024.
- 13 Sep 2022 Interim Results( At data cutoff (May 31, 2022) assessing efficacy and safety of Pembrolizumab with chemoradiation therpy vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma presented at the 47th European Society for Medical Oncology Congress